Recent Research Analysts’ Ratings Changes for Kiniksa Pharmaceuticals International (KNSA)

A number of research firms have changed their ratings and price targets for Kiniksa Pharmaceuticals International (NASDAQ: KNSA):

  • 10/30/2026 – Kiniksa Pharmaceuticals International had its price target raised by JPMorgan Chase & Co. from $107.00 to $122.00. They now have an “overweight” rating on the stock.
  • 10/28/2026 – Kiniksa Pharmaceuticals International was downgraded by Weiss Ratings from “buy (b-)” to “hold (c-)”.
  • 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by The Goldman Sachs Group from $90.00 to $101.00. They now have a “buy” rating on the stock.
  • 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $99.00 to $102.00. They now have an “outperform” rating on the stock.
  • 10/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wells Fargo & Company from $87.00 to $110.00. They now have an “overweight” rating on the stock.
  • 10/8/2026 – Kiniksa Pharmaceuticals International was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
  • 9/30/2026 – Kiniksa Pharmaceuticals International is now covered by Wells Fargo & Company. They set an “overweight” rating and a $87.00 price target on the stock.

Kiniksa Pharmaceuticals International Stock Down 0.9%

KNSA stock traded down $0.85 during midday trading on Monday, reaching $95.47. The company’s stock had a trading volume of 115,173 shares, compared to its average volume of 701,583. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $99.31. The stock has a market cap of $7.50 billion, a PE ratio of 73.44 and a beta of 0.07. The business’s 50-day simple moving average is $82.18 and its 200-day simple moving average is $62.70.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, COO Ross Moat sold 75,608 shares of the business’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $93.13, for a total value of $7,041,373.04. Following the completion of the transaction, the chief operating officer directly owned 10,294 shares of the company’s stock, valued at approximately $958,680.22. The trade was a 88.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 36,783 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $92.16, for a total value of $3,389,921.28. Following the completion of the sale, the chief financial officer owned 20,854 shares of the company’s stock, valued at $1,921,904.64. This trade represents a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 842,302 shares of company stock valued at $78,587,130. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

Read More

Receive News & Ratings for Kiniksa Pharmaceuticals International plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International plc and related companies with MarketBeat.com's FREE daily email newsletter.